PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsHepatitis b immune globulin
Hepatitis b immune globulin
Hepatitis b immune globulin is an unknown pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
hepagam bBiologic Licensing Application2021-03-23
hyperhep b s/dBiologic Licensing Application2010-10-27
nabi-hbBiologic Licensing Application2022-11-22
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
Code
Description
J1571
Injection, hepatitis b immune globulin (hepagam b), intramuscular, 0.5 ml
J1573
Injection, hepatitis b immune globulin (hepagam b), intravenous, 0.5 ml
Clinical
Clinical Trials
126 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hepatitis bD006509920192730101
HepatitisD006505HP_0012115K75.991918262593
Hepatitis aD006506EFO_0007305B1581811241775
Chronic hepatitis bD019694EFO_0004239B18.151122727
Chronic hepatitisD006521K73.9282315
Hiv infectionsD015658EFO_0000764B201179
Hepatitis cD006526B19.2369
InfectionsD007239EFO_000054411248
Liver transplantationD016031EFO_0010682121227
Communicable diseasesD00314111136
Show 13 more
Indications Phases 3
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Liver cirrhosisD008103EFO_0001422K74.0134
LymphomaD008223C85.9112
MalariaD008288EFO_0001068B54112
Chronic renal insufficiencyD051436N1811
Kidney diseasesD007674EFO_0003086N0811
FibrosisD00535511
Rectal neoplasmsD01200411
End stage liver diseaseD058625EFO_1001311K72.111
Lung transplantationD01604011
B-cell lymphomaD01639311
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C80112
Hepatitis b virusD006515112
Ebola hemorrhagic feverD019142EFO_0007243A98.411
Marburg virus diseaseD008379EFO_0007358A98.311
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hepatocellular carcinomaD006528C22.044
Liver neoplasmsD008113EFO_1001513C22.044
Acquired immunodeficiency syndromeD000163EFO_0000765B2022
CarcinomaD002277C80.022
Immunosuppression therapyD00716511
Pregnancy rateD01887311
Substance-related disordersD019966EFO_0003890F1311
Intravenous substance abuseD01581911
Medication adherenceD055118EFO_000634411
Risk-takingD01230911
Show 16 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameHepatitis b immune globulin
INN
Description
Hepatitis B immunoglobulin (HBIG) is a human immunoglobulin that is used to prevent the development of hepatitis B and is used for the treatment of acute exposure to HBsAg.
Classification
Protein
Drug classantineoplastics (mitotic inhibitors; tubulin binders)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID
RxCUI
ChEMBL IDCHEMBL2108512
ChEBI ID
PubChem CID
DrugBankDB05276
UNII ID
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 2,348 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
118 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use